[en] The present study reviews the literature on inflammation and remodelling mechanisms in chronic obstructive pulmonary disease (COPD). The development of COPD is associated with chronic pulmonary inflammation. Immunity (innate or adaptive) plays a role in its onset and continuation. Airways inflammation alters bronchial structure/function relations: increased bronchial wall thickness, increased bronchial smooth muscle tone, seromucosal gland hypersecretion and loss of elastic structures. Circulating markers of pulmonary inflammation indicate its systemic dissemination. Oxidative stress plays a major role in the onset and persistence of tissue abnormalities. The determinants of extra- and intra-cellular redox control are only partially known. Susceptibility genes, antioxidant system insufficiency and reduced levels of anti-age molecules and of histone deacetylation are also involved. The molecular and cellular targets of inflammation and remodelling are numerous and complex. Currently, tools exist to limit inflammation in COPD but not to act on structural remodelling.
Saetta M, Di Stefano A, Maestrelli P, Ferraresso A, Drigo R, Potena A, et al. Activated T-lymphocytes and macrophages in bronchial mucosa of subjects with chronic bronchitis. Am Rev Respir Dis 1993;147:301-6. (Pubitemid 23044899)
Anthonisen NR, Connett JE, Murray RP. Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med 2002;166:675-9. (Pubitemid 34971849)
Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004;350:2645-53. (Pubitemid 38787999)
Cosio MG, Saetta M, Agusti A. Immunologic aspects of chronic obstructive pulmonary disease. N Engl J Med 2009;360:2445-54.
Jiang D, Liang J, Li Y, Noble PW. The role of Toll-like receptors in non-infectious lung injury. Cell Res 2006;16:693-701. (Pubitemid 44258922)
Klune JR, Dhupar R, Cardinal J, Billiar TR, Tsung A. HMGB1: endogenous danger signaling. Mol Med 2008;14:476-84.
Mills PR, Davies RJ, Devalia JL. Airway epithelial cells, cytokines, and pollutants. Am J Respir Crit Care Med 1999;160: S38-43.
Hammad H, Lambrecht BN. Dendritic cells and epithelial cells: linking innate and adaptative immunity in asthma. Nat Rev Immunol 2008;8:193-204. (Pubitemid 351323293)
Abbas AK, Lichtman AH, Pober JS. Activation of T lymphocytes. In: Cellular and molecular immunology. Philadelphia PA, USA: Saunders; 2000. p. 161-80.
Freeman CM, Martinez FJ, Han MK, Ames TM, Chensue SW, Todt JC, et al. Lung dendritic cell expression of maturation molecules increases with worsening chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009;180:1179-88.
Brusselle GG, Demoor T, Bracke KR, Brandsma CA, Timens W. Lymphoid follicles in (very) severe COPD: beneficial or harmful? Eur Respir J 2009;34:219-30.
van der Strate BW, Postma DS, Brandsma CA, Melgert BN, Luinge MA, Geerlings M, et al. Cigarette smoke-induced emphysema: a role for the B cell? Am J Respir Crit Care Med 2006;173:751-8.
Lee SH, Goswami S, Grudo A, Song LZ, Bandi V, Goodnight-White S, et al. Antielastin autoimmunity in tobacco smokinginduced emphysema. Nat Med 2007;13:567-9. (Pubitemid 46828488)
Greene CM, Low TB, O'Neill SJ, McElvaney NG. Anti-prolineglycineproline or antielastin autoantibodies are not evident in chronic inflammatory lung disease. Am J Respir Crit Care Med 2010;181:31-5.
Berger P, Laurent F, Begueret H, Perot V, Rouiller R, Raherison C, et al. Structure and function of small airways in smokers: relationship between air trapping at CT and airway inflammation. Radiology 2003;228:85-94. (Pubitemid 36736073)
Berger P, Marthan R, Tunon de Lara JM. The pathophysiological role of smooth muscle cells in bronchial inflammation. Rev Mal Respir 2002;19:778-94. (Pubitemid 36019716)
Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008;31:416-69.
Comandini A, Rogliani P, Nunziata A, Cazzola M, Curradi G, Saltini C. Biomarkers of lung damage associated with tobacco smoke in induced sputum. Respir Med 2009;103:1592-613.
Rogers DF. Physiology of airway mucus secretion and pathophysiology of hypersecretion. Respir Care 2007;52:1134-46 [discussion 1146-9].
Churg A, Cosio M, Wright JL. Mechanisms of cigarette smokeinduced COPD: insights from animal models. Am J Physiol Lung Cell Mol Physiol 2008;294:612-31.
Di Francia M, Barbier D, Mege JL, Orehek J. Tumor necrosis factor-alpha levels and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1994;150:1453-5. (Pubitemid 24356667)
Donaldson GC, Seemungal TA, Patel IS, Bhowmik A, Wilkinson TM, Hurst JR, et al. Airway and systemic inflammation and decline in lung function in patients with COPD. Chest 2005;128:1995-2004. (Pubitemid 41507533)
Sin DD, Leung R, Gan WQ, Man SP. Circulating surfactant protein D as a potential lung-specific biomarker of health outcomes in COPD: a pilot study. BMC Pulm Med 2007;7:13.
Bozinovski S, Hutchinson A, Thompson M, Macgregor L, Black J, Giannakis E, et al. Serum amyloid is a biomarker of acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008;177:269-78. (Pubitemid 351198369)
Chao J, Wood JG, Blanco VG, Gonzalez NC. The systemic inflammation of alveolar hypoxia is initiated by alveolar macrophage-borne mediator (s). Am J Respir Cell Mol Biol 2009;41:573-82.
Marquis K, Debigaré R, Lacasse Y, LeBlanc P, Jobin J, Carrier G, et al. Midthigh muscle cross-sectional area is a better predictor of mortality than body mass index in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;166:809-13.
Wagner PD. Skeletal muscles in chronic obstructive pulmonary disease: deconditioning, or myopathy? Respirology 2006;11:681-6. (Pubitemid 44581430)
Handschin C, Spiegelman BM. The role of exercise and PGC1alpha in inflammation and chronic disease. Nature 2008;454:463-9.
Yende S, Waterer GW, Tolley EA, Newman AB, Bauer DC, Taaffe DR, et al. Inflammatory markers are associated with ventilatory limitation and muscle dysfunction in obstructive lung disease in well functioning elderly subjects. Thorax 2006;61:10-6. (Pubitemid 43106971)
Agusti A, Morla M, Sauleda J, Saus C, Busquets X. NF-kappaB activation and iNOS upregulation in skeletal muscle of patients with COPD and low body weight. Thorax 2004;59:483-7. (Pubitemid 38797520)
Montes de Oca M, Rassulo J, Celli BR. Respiratory muscle and cardiovascular function during exercise in very severe COPD. Am J Respir Crit Care Med 1996;154:1284-9. (Pubitemid 26391170)
Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000;102:2165-8.
Eickhoff P, Valipour A, Kiss D, Schreder M, Cekici L, Geyer K, et al. Determinants of systemic vascular function in patients with stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008;178:1211-8.
Chaouat A, Naeije R, Weitzenblum E. Pulmonary hypertension in COPD. Eur Respir J 2008;32:1371-85.
Fresquet F, Pourageaud F, Leblais V, Brandes RP, Savineau JP, Marthan R, et al. Role of reactive oxygen species and gp91phox in endothelial dysfunction of pulmonary arteries induced by chronic hypoxia. Br J Pharmacol 2006;148:714-23. (Pubitemid 43996780)
Chaouat A, Savale L, Chouaid C, Tu L, Sztrymf B, Canuet M, et al. Role for interleukin-6 in COPD-related pulmonary hypertension. Chest 2009;136:678-87.
Jorgensen NR, Schwarz P. Osteoporosis in chronic obstructive pulmonary disease patients. Curr Opin Pulm Med 2008;14:122-7. (Pubitemid 351323163)
Lam KB, Jordan RE, Jiang CQ, Thomas GN, Miller MR, Zhang WS, et al. Airflow obstruction and the metabolic syndrome: the Guangzhou Biobank Cohort Study. Eur Respir J 2010;35:317-23.
MacNee W. Pulmonary and systemic oxidant/antioxidant imbalance in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005;2:50-60. (Pubitemid 40562963)
Stevenson CS, Koch LG, Britton SL. Aerobic capacity, oxidant stress, and chronic obstructive pulmonary disease-a new take on an old hypothesis. Pharmacol Ther 2006;110:71-82. (Pubitemid 43248726)
Borrill ZL, Roy K, Singh D. Exhaled breath condensate biomarkers in COPD. Eur Respir J 2008;32:472-86.
Repine JE, Bast A, Lankhorst I. Oxidative stress in chronic obstructive pulmonary disease. Oxidative Stress Study Group. Am J Respir Crit Care Med 1997;156:341-57. (Pubitemid 27351964)
Comhair SA, Erzurum SC. Antioxidant responses to oxidantmediated lung diseases. Am J Physiol Lung Cell Mol Physiol 2002;283: L246-55. (Pubitemid 34803980)
Tzortzaki EG, Siafakas NM. A hypothesis for the initiation of COPD. Eur Respir J 2009;34:310-5.
Guenegou A, Boczkowski J, Aubier M, Neukirch F, Leynaert B. Interaction between a heme oxygenase-1 gene promoter polymorphism and serum beta-carotene levels on 8-year lung function decline in a general population: the European Community Respiratory Health Survey (France). Am J Epidemiol 2008;167:139-44.
Rahman I, Adcock IM. Oxidative stress and redox regulation of lung inflammation in COPD. Eur Respir J 2006;28:219-42. (Pubitemid 44914279)
Ito K, Barnes PJ. COPD as a disease of accelerated lung aging. Chest 2009;135:173-80.
Barnes PJ. Role of HDAC2 in the pathophysiology of COPD. Annu Rev Physiol 2009;71:451-64.
Zhang X, Mahmudi-Azer S, Connett JE, Anthonisen NR, He JQ, Paré PD, et al. Association of Hck genetic polymorphisms with gene expression and COPD. Hum Genet 2007;120:681-90. (Pubitemid 44942852)
Maestrelli P, Páska C, Saetta M, Turato G, Nowicki Y, Monti S, et al. Decreased haem oxygenase-1 and increased inducible nitric oxide synthase in the lung of severe COPD patients. Eur Respir J 2003;21:971-6. (Pubitemid 36675612)
